Patents by Inventor Michael O. Chaney

Michael O. Chaney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-Containing Compositions
    Publication number: 20110046103
    Abstract: The treatment of neurological disorders using cefazolin compositions and pharmaceutical compositions including oral dosage forms that include cefazolin compositions are described.
    Type: Application
    Filed: November 3, 2010
    Publication date: February 24, 2011
    Applicant: Revaax Pharmaceuticals, LLC
    Inventors: Gary A. Koppel, Michael O. Chaney
  • Oral neurotherapeutic cephalosporin sulfoxide and sulfone-containing compositions
    Patent number: 7833998
    Abstract: The treatment of neurological disorders using cephalosporin sulfoxide-containing and/or cephalosporin sulfone-containing compositions and pharmaceutical compositions including oral dosage forms that include cephalosporin sulfoxide and/or sulfone-containing compositions are described.
    Type: Grant
    Filed: August 24, 2004
    Date of Patent: November 16, 2010
    Assignee: Revaax Pharmaceuticals, LLC
    Inventors: Gary A. Koppel, Michael O. Chaney
  • NEUROTHERAPEUTIC COMPOSITION AND METHOD THEREFOR
    Publication number: 20100249090
    Abstract: Neurotherapeutically effective pharmaceutical compositions are described that include carboxypeptidase E inhibitors. One class of carboxypeptidase E inhibitors found to exhibit significant neurotropic activity are ?-lactam compounds, particularly penam and cephem ?-lactam antibiotics and non-antibiotic derivatives thereof.
    Type: Application
    Filed: May 13, 2010
    Publication date: September 30, 2010
    Inventors: Gary A. Koppel, Michael O. Chaney
  • BETA-LACTAM CANNABINOID RECEPTOR MODULATORS
    Publication number: 20100016274
    Abstract: Described herein are substituted 2-(azetidin-2-on-1-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CB1) and/or cannabinoid-2 (CB2) receptor. Also described herein are methods for treating mammals in need of relief from disease states associated with and responsive to modulation of the CB1 and/or CB2 receptor activity.
    Type: Application
    Filed: September 14, 2007
    Publication date: January 21, 2010
    Inventors: Gary A. Koppel, Michael O. Chaney
  • Oral Neurotherapeutic Cefazolin Compositons
    Publication number: 20080176825
    Abstract: The treatment of neurological disorders using cefazolin compositions and pharmaceutical compositions including oral dosage forms that include cefazolin compositions are described.
    Type: Application
    Filed: August 24, 2004
    Publication date: July 24, 2008
    Inventors: Gary A. Koppel, Michael O. Chaney
  • Neurotherapeutic composition and method therefor
    Publication number: 20030158172
    Abstract: Neurotherapeutically pharmaceutical effective compositions are prepared using carboxypeptidase E inhibitors. One class of carboxypeptidase E inhibitors found to exhibit significant neurotropic activity are &bgr;-lactam compounds, particularly penam and cephem &bgr;-lactam antibiotics and non-antibiotic derivatives thereof.
    Type: Application
    Filed: August 20, 2002
    Publication date: August 21, 2003
    Inventors: Gary A. Koppel, Michael O. Chaney
  • Neurotherapeutic use of carboxypeptidase inhibitors
    Patent number: 6489319
    Abstract: Administration of inhibitors of carboxypeptidase E provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior and enhanced cognition. Certain &bgr;-Lactam antibiotics, most significantly, certain 1-oxa-1-dethia cephems with blood brain barrier transport, exhibit potent therapeutic neurologic activity.
    Type: Grant
    Filed: February 14, 2001
    Date of Patent: December 3, 2002
    Assignee: Revaax Pharmaceuticals, LLC
    Inventors: Gary A. Koppel, Michael O. Chaney
  • Neurotherapeutic use of carboxypeptidase inhibitors
    Publication number: 20020028761
    Abstract: Administration of inhibitors of carboxypeptidase E provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior and enhanced cognition. Certain &bgr;-Lactam antibiotics, most significantly, certain 1-oxa-1-dethia cephems with blood brain barrier transport, exhibit potent therapeutic neurologic activity.
    Type: Application
    Filed: February 14, 2001
    Publication date: March 7, 2002
    Inventors: Gary A. Koppel, Michael O. Chaney
  • Combinatorial process for synthesizing azetidinone analogs
    Patent number: 5759865
    Abstract: This invention relates to a combinatorial process for synthesizing a library of azetidinone peptide-like compounds. The compounds are synthesized as mixtures from a common azetidinone intermediate. The compounds are biologically active as inhibitors of the Vasopressin (V1a) receptor.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: June 2, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Michael O. Chaney, Robin D. Cooper, David C. Hunden, Gary A. Koppel, Jeffrey J. Skelton